Document is current
Any future updates will be listed below
-
Authors
Sliepen, Kwinten https://orcid.org/0000-0003-1414-0648
Radić, Laura
Capella-Pujol, Joan https://orcid.org/0000-0002-7375-7958
Watanabe, Yasunori
Zon, Ian https://orcid.org/0000-0003-4346-0739
Chumbe, Ana https://orcid.org/0000-0003-0870-5075
Lee, Wen-Hsin https://orcid.org/0000-0001-9445-6671
de Gast, Marlon
Koopsen, Jelle
Koekkoek, Sylvie
del Moral-Sánchez, Iván
Brouwer, Philip J. M.
Ravichandran, Rashmi
Ozorowski, Gabriel https://orcid.org/0000-0002-9695-8138
King, Neil P. https://orcid.org/0000-0002-2978-4692
Ward, Andrew B. https://orcid.org/0000-0001-7153-3769
van Gils, Marit J. https://orcid.org/0000-0003-3422-8161
Crispin, Max https://orcid.org/0000-0002-1072-2694
Schinkel, Janke
Sanders, Rogier W. https://orcid.org/0000-0002-2324-8573
-
Funding
Funding for this research was provided by:
Amsterdam institute for Infection and Immunity of the Amsterdam UMC
- License Information
-
More Information
Article History
Received: 24 February 2022
Accepted: 14 November 2022
First Online: 25 November 2022
Competing interests
: N.P.K. is a co-founder and shareholder of Icosavax, a company that has licensed patent applications regarding the I53-50 nanoparticle system, and N.P.K. is a member of Icosavax’s Scientific Advisory Board. All other authors declare no competing interests.
